甘李药业股份有限公司 2025 年第一次临时股东大会 会议资料 二〇二五年十一月 1 甘李药业股份有限公司 2025 年第一次临时股东大会 甘李药业股份有限公司 2025 年第一次临时股东大会会议议程 主持人：陈伟 2025 年 11 月 17 日 | 序号 | 会议事项 | | --- | --- | | 一 | 宣布会议开始 | | 二 | 致欢迎辞 | | 三 | 宣布大会参加人数、代表股数、会议有效。介绍会议出席人员，介绍律师事务所 见证律师 | | 四 | 主持人提议监票人、计票人与记录人 | | 五 | 提示投票表决方式 | | 六 | 股东逐项审议议案： | | 非累积投票议案 | | | 1 | 《关于取消监事会、修订<公司章程>并办理工商变更登记的议案》 | | 2 | 《关于制定及修订公司部分治理制度的议案》 | | 2.1 | 《关于修订<甘李药业股份有限公司股东会议事规则>的议案》 | | 2.2 | 《关于修订<甘李药业股份有限公司董事会议事规则>的议案》 | | 2.3 | 《关于修订<甘李药业股份有限公司对外担保制度>的议案》 | | 2.4 | 《关于修订<甘李药业股份有限公司 ...

甘李药业所属申万行业为：医药生物-生物制品-其他生物制品。所属概念板块包括：创新药、生物医 药、医疗器械、多肽药、基金重仓等。 截至9月30日，甘李药业股东户数9.47万，较上期增加22.53%；人均流通股5889股，较上期减少 17.81%。2025年1月-9月，甘李药业实现营业收入30.47亿元，同比增长35.73%；归母净利润8.18亿元， 同比增长61.32%。 11月12日，甘李药业盘中上涨2.03%，截至09:50，报65.41元/股，成交1.78亿元，换手率0.49%，总市值 390.70亿元。 资金流向方面，主力资金净流入897.83万元，特大单买入652.78万元，占比3.68%，卖出325.78万元，占 比1.83%；大单买入4254.96万元，占比23.96%，卖出3684.13万元，占比20.75%。 甘李药业今年以来股价涨51.74%，近5个交易日涨1.92%，近20日跌7.73%，近60日涨7.21%。 资料显示，甘李药业股份有限公司位于北京市通州区漷县镇南凤西一路8号，成立日期1998年6月17日， 上市日期2020年6月29日，公司主营业务涉及重组胰岛素类似物原料药及注射剂的研 ...

Group 1 - The fifth meeting of the fifth board of directors of Gann Li Pharmaceutical Co., Ltd. was held on November 10, 2025, with all nine directors present, confirming the legality and validity of the meeting [2][5][24]. - The board unanimously approved the proposal regarding the addition of related parties and the expected daily related transactions for 2025 and 2026 [3][9][25]. - The proposal was reviewed and approved by the independent directors and does not require submission to the shareholders' meeting [4][6][9]. Group 2 - The company plans to transfer 70% of the equity of its wholly-owned subsidiary, Gann Medical Technology Jiangsu Co., Ltd., to Guangdong Hengqin Ganling Enterprise Management Co., Ltd. in two steps, resulting in Gann Medical becoming an associated company [12][16]. - The expected daily related transactions will include purchasing goods and providing services between the company and Gann Medical, with specific amounts projected for 2025 and 2026 [13][22]. - The pricing for these transactions will adhere to market prices and will be negotiated between the parties, ensuring fairness and compliance with market principles [19][20]. Group 3 - The board and supervisory committee confirmed that the daily related transactions are normal business activities and will not adversely affect the company's independence or the interests of shareholders, especially minority shareholders [10][22][25]. - The financial data of Gann Medical indicates that it is operationally sound and capable of fulfilling its obligations [18]. - The company will maintain independence in its operations and will not become overly reliant on the related parties [22].

Core Insights - The article highlights the trend of leading companies in the pharmaceutical industry optimizing resource allocation through strategic partnerships, exemplified by Ganli Pharmaceutical's transfer of control over its subsidiary, Gangan Medical Technology Jiangsu Co., Ltd. to Hillhouse Capital [1] Group 1: Strategic Focus and Resource Optimization - Ganli Pharmaceutical is focusing on its core business by transferring control of Gangan Jiangsu, which aligns with its strategy to optimize non-core asset allocation and concentrate resources on innovative drug development for metabolic diseases like diabetes and obesity [2] - The transaction represents a key action in Ganli Pharmaceutical's strategy to enhance its technological competitiveness and market influence in core therapeutic areas [2] Group 2: Innovation and Development - Gangan Jiangsu, driven by innovation, specializes in high-quality drug delivery devices and has established a comprehensive quality management and regulatory compliance system that meets international standards [2] - Following the strategic partnership, Gangan Jiangsu is expected to enter a new phase of development with enhanced focus and vitality, supported by Hillhouse Capital's long-term strategic planning and diverse resource backing [2] Group 3: Ecosystem Synergy and Value Enhancement - The collaboration between Ganli Pharmaceutical and Hillhouse Capital is seen as a significant milestone that promotes resource integration and efficiency improvement within the pharmaceutical industry [3] - The partnership aims to enhance the stability and efficiency of the insulin supply chain, while Gangan Jiangsu will expand its business scope to provide customized solutions for other pharmaceutical companies reliant on drug delivery devices [3] - Hillhouse Capital's accumulated resources in the global healthcare sector are expected to create new opportunities for collaboration in areas such as joint drug development and comprehensive health management services for diabetes patients [3]

证券代码：603087 证券简称：甘李药业 公告编号：2025-076 甘李药业股份有限公司 关于新增关联方、新增 2025 年度及 2026 年度日常关 联交易预计的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 《关于公司新增关联方、新增 2025 年度及 2026 年度日常关联交易预计 的议案》已经公司第五届董事会独立董事专门会议 2025 年第一次会议、第五届 董事会第五次会议、第五届监事会第五次会议审议通过，无需提交公司股东大会 审议。 一、日常关联交易基本情况 （一）日常关联交易履行的审议程序 甘李药业股份有限公司（以下简称"公司"）于 2025 年 11 月 10 日召开了第 五届董事会第五次会议及第五届监事会第五次会议，审议通过了《关于公司新增 关联方、新增 2025 年度及 2026 年度日常关联交易预计的议案》，公司全体董事、 监事一致表决通过，无需回避表决。根据《上海证券交易所股票上市规则》相关 规定，本次日常关联交易金额未达到公司最近一期经审计净资产绝对值的 5%， 无需提交公司股 ...

本公司监事会及全体监事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 一、监事会会议召开情况 甘李药业股份有限公司（"公司"）第五届监事会第五次会议于 2025 年 11 月 5 日以电子邮件方式发出会议通知和会议材料，2025 年 11 月 10 日在公司五 层会议室以现场会议的形式召开。本次会议由监事会主席张立主持。应出席监事 3 名，实际出席监事 3 名。本次会议的召开符合《公司法》和《公司章程》的有 关规定，会议决议合法有效。 二、监事会会议审议情况 经与会监事审议表决，一致通过如下议案： 证券代码：603087 证券简称：甘李药业 公告编号：2025-075 甘李药业股份有限公司 第五届监事会第五次会议决议公告 经审议，监事会认为：公司与关联方签署协议并进行日常交易为正常经营范 围内的购销行为，符合公司日常生产经营实际情况，交易具有商业合理性，交易 定价遵循公平、公正、公允的市场化原则，不影响公司的独立性，不存在损害公 司和股东利益，特别是中小股东利益的情况，公司亦不会因关联交易而对关联方 形成依赖。 具体内容详见公司于同日在上海证券交易 ...

（一）审议通过了《关于公司新增关联方、新增 2025 年度及 2026 年度日常 关联交易预计的议案》 证券代码：603087 证券简称：甘李药业 公告编号：2025-074 甘李药业股份有限公司 第五届董事会第五次会议决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 一、董事会会议召开情况 甘李药业股份有限公司（"公司"）第五届董事会第五次会议于 2025 年 11 月 5 日以电子邮件方式发出会议通知和会议材料，2025 年 11 月 10 日在公司五 层会议室以现场结合通讯方式召开。本次会议由董事长陈伟先生主持。应出席董 事 9 名，实际出席董事 9 名。公司监事和高级管理人员列席会议。本次会议的召 开符合《公司法》和《公司章程》的有关规定，会议决议合法有效。 二、董事会会议审议情况 经与会董事审议表决，一致通过如下议案： 同意公司新增关联方、新增 2025 年度及 2026 年度日常关联交易预计。 具体内容详见公司于同日在上海证券交易所网站披露的《甘李药业股份有限 公司关于新增关联方、新增 2025 年度及 2 ...

Group 1 - The core point of the article is that Ganli Pharmaceutical (SH 603087) held its fifth board meeting on November 10, 2025, to discuss new related parties and expected daily related transactions for 2025 and 2026 [1] - For the year 2024, Ganli Pharmaceutical's revenue composition is entirely from the pharmaceutical manufacturing industry, accounting for 100.0% [1] - As of the time of reporting, Ganli Pharmaceutical has a market capitalization of 38.6 billion yuan [1]

Core Insights - The meeting on November 3 involved the Economic and Commercial Counselor of the Chinese Mission to the African Union, who met with the International Business Director of Ganli Pharmaceutical Co., Ltd. to discuss the company's operations in Africa [1] Group 1 - The company is actively engaging in business development in Africa and has been welcomed to join the China-Africa Business Council [1] - The meeting emphasized the importance of the company's role in supporting high-quality development of China-Africa cooperation [1]

Investment Rating - The report maintains a "Buy" rating for the company, with a target price of 67.2 yuan based on a 28x PE valuation for 2026 [3][5]. Core Insights - The company continues to show strong growth, with a revenue of 30.5 billion yuan in the first three quarters of 2025, representing a year-on-year increase of 35.7%. The net profit attributable to the parent company reached 8.2 billion yuan, up 61.3% year-on-year [10]. - The company has successfully expanded its international business, particularly in emerging markets, with significant contracts in Brazil that could contribute to future revenue growth [10]. Financial Performance Summary - Revenue projections for 2025-2027 are 42.02 billion yuan, 51.81 billion yuan, and 61.15 billion yuan, respectively, with year-on-year growth rates of 38.0%, 23.3%, and 18.0% [8]. - The company's gross margin is expected to improve to 78.7% in 2025, while the net margin is projected to reach 27.1% [8]. - Earnings per share (EPS) are forecasted to be 1.91 yuan, 2.40 yuan, and 2.84 yuan for 2025, 2026, and 2027, respectively [8].